Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Myopia News
Eyenovia Scraps Phase III Study of Low-Dose Atropine Candidate in Myopia
Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...
Zeiss Gains US Approval for MEL 90 Excimer Laser
Carl Zeiss Meditec gained US FDA approval on Dec. 4 for its MEL 90 excimer laser, the next-generation iteration of its MEL 80 for LASIK surgery. The MEL 90’s US labeling is for correction of myopia...
Eyenovia Scraps Phase III Study of Low-Dose Atropine in Myopia After Endpoint Missed
Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...
Ophthalmologists Compare Myopia Interventions at WOC as Prevalence Soars
Myopia—especially progression of myopia—is getting increased attention from industry and physicians, as evidenced by the sheer number of studies published on the topic. Additionally, data showing h...
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
July 2024 Ophthalmic News Briefs
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Sydnexis Appoints Perry J. Sternberg as Chief Executive Officer
Sydnexis, of Del Mar, California, announced July 16 that Perry J. Sternberg had been appointed chief executive officer and as a member of the board of directors. He will join the company on Aug. 5,...
Vyluma Plans to Resubmit NDA for Low-Dose Atropine for Myopia after Meeting with US FDA
Vyluma announced June 18 that it had met with the US FDA’s Division of Ophthalmology to discuss resubmitting its new drug application (NDA) for lead compound NVK002, a low-dose formulation of atrop...
June 2024 Ophthalmic News Briefs
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
Dopavision Sees Positive Results in Trial of Photobiomodulation for Myopia
Germany’s Dopavision reported May 28 that its MyopiaX photobiomodulation system targeting myopia showed signals of clinical effect on the rate of progression at six months in a proof-of-concept tri...
EU Accepts Vyluma’s Marketing Application for Low-Dose Atropine in Childhood Myopia
Vyluma reported May 29 that the European Medicines Agency had accepted its marketing application for lead compound NVK002, a low-dose formulation of atropine targeting childhood myopia. NVK002 is a...
2024 APAO Congress Brainstorms How to Expand Access to Eye Care; Companies Showcase Tech Boom
Nearly 7,800 delegates attended the 2024 congress of the Asia-Pacific Academy of Ophthalmology in southern Bali from Feb. 22-25. The 253 sessions and 120 exhibits spread across four floors in two n...
Santen Files for Marketing Approval in Japan for Atropine Drops to Delay Myopia
Santen Pharmaceutical announced Feb. 28 that it had filed for marketing approval in Japan of DE-127 (0.025% atropine sulfate hydrate eye drop), designed to slow the progression of myopia. The produ...
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb
Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...
US FDA PDUFA Target Action Dates for Ophthalmic Candidates, 2024
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...
Eyenovia Reacquires Rights to MicroPine in US, Canada from Bausch + Lomb
Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...
US Refractive Surgeons Grapple with Treatment Options for High Myopes
Surgeons attending the Refractive Subspecialty Day at the 2023 AAO meeting in San Francisco debated the ideal treatment options for patients with moderate to high myopia. Practices shared widely di...
Emerging Companies Pursuing Ophthalmic Indications, August 2023
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.